[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484341":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":39,"centralContacts":50,"locations":59,"responsibleParty":121,"collaborators":124,"id":130,"slug":131,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":132,"sex":137,"minAge":138,"maxAge":28,"enrollmentInfo":139,"targetDuration":28,"studyType":142,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":62,"whyStopped":28,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Decolonization","ACTIVE_COMPARATOR","Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).",[13,14],"Drug: 4% Chlorhexidine Gluconate","Drug: 2% Mupirocin",{"label":16,"type":17,"description":18,"interventionNames":19},"Routine Care","PLACEBO_COMPARATOR","Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.",[20,21],"Drug: Soap Without Antiseptic Properties (Placebo)","Drug: Placebo Nasal Ointment",[23,29,33,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","4% Chlorhexidine Gluconate","Used for daily showering\u002Fbathing for 30 days after hospital discharge.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"2% Mupirocin","Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.",[9],{"type":24,"name":34,"description":26,"armGroupLabels":35,"otherNames":28},"Soap Without Antiseptic Properties (Placebo)",[16],{"type":24,"name":37,"description":31,"armGroupLabels":38,"otherNames":28},"Placebo Nasal Ointment",[16],[40,43,47],{"name":41,"affiliation":5,"role":42},"Susan Huang, MD, MPH","PRINCIPAL_INVESTIGATOR",{"name":44,"affiliation":45,"role":46},"Deborah Yokoe, MD, MPH","University of California, San Francisco","STUDY_DIRECTOR",{"name":48,"affiliation":49,"role":46},"Stuart Cohen, MD","University of California, Davis",[51,55],{"name":41,"role":52,"phone":53,"phoneExt":28,"email":54},"CONTACT","(949) 824-5073","sshuang@hs.uci.edu",{"name":56,"role":52,"phone":57,"phoneExt":28,"email":58},"Raveena Singh, MA","(949) 824-9285","ravsingh@hs.uci.edu",[60,80,93,107],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Hoag Memorial Hospital Presbyterian","RECRUITING","Newport Beach","California","92663","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-117.92895,33.61891,{"lat":72,"lon":71},[75,79],{"name":76,"role":52,"phone":77,"phoneExt":28,"email":78},"Philip Robinson, MD","949-764-5752","philip.robinson@hoag.org",{"name":76,"role":42,"phone":28,"phoneExt":28,"email":28},{"facility":81,"status":62,"city":82,"state":64,"zip":83,"country":66,"countryCode":67,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"University of California, Irvine Medical Center","Orange","92868",{"type":69,"coordinates":85},[86,87],-117.85311,33.78779,{"lat":87,"lon":86},[90,92],{"name":41,"role":52,"phone":91,"phoneExt":28,"email":54},"9498245073",{"name":41,"role":42,"phone":28,"phoneExt":28,"email":28},{"facility":94,"status":62,"city":95,"state":64,"zip":96,"country":66,"countryCode":67,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"University of California, Davis Medical Center","Sacramento","95817",{"type":69,"coordinates":98},[99,100],-121.4944,38.58157,{"lat":100,"lon":99},[103,106],{"name":48,"role":52,"phone":104,"phoneExt":28,"email":105},"916-734-3741","stcohen@ucdavis.edu",{"name":48,"role":42,"phone":28,"phoneExt":28,"email":28},{"facility":108,"status":62,"city":109,"state":64,"zip":110,"country":66,"countryCode":67,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"University of California, San Francisco Medical Center","San Francisco","94143",{"type":69,"coordinates":112},[113,114],-122.41942,37.77493,{"lat":114,"lon":113},[117,120],{"name":44,"role":52,"phone":118,"phoneExt":28,"email":119},"415-502-4165","deborah.yokoe@ucsf.edu",{"name":44,"role":42,"phone":28,"phoneExt":28,"email":28},{"type":42,"investigatorFullName":122,"investigatorTitle":123,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Susan Huang","Professor, Division of Infectious Diseases and Medical Director, Epidemiology and Infection Prevention",[125,126,127,129],{"name":49,"class":6},{"name":45,"class":6},{"name":128,"class":6},"University of Massachusetts, Amherst",{"name":61,"class":6},"100484341","phase-4-decolonization-to-reduce-after-surgery-events-of-surgical-site-infection-100484341",false,"NCT05586776","Decolonization to Reduce After-Surgery Events of Surgical Site Infection","DECREASE SSI","Inclusion Criteria:\n\n* 18 years of age or older\n* Recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. For cesarean section, recruitment restricted to BMI ≥ 40.\n* Able to communicate regularly by phone\n* Able to bathe, shower or have this task performed by a caregiver\n\nExclusion Criteria:\n\n* Transfer to an acute care hospital\n* Discharged to receive end-of-life hospice measures\n* Discharged more than 14 days after surgery\n* Allergic to mupirocin and\u002For chlorhexidine\n* Active infection at enrollment\\*\n\n  \\*Refers to\n  1. Infections requiring systemic antibacterial agents, so viral illness (e.g., COVID, flu) is not an exclusion.\n  2. Topical antibacterial agents do not count toward exclusion (e.g., topical products for acne)\n  3. Prophylactic antibacterial agents do not count toward exclusion\n* Surgical incision not closed at discharge","ALL","18 Years",{"count":140,"type":141},2700,"ESTIMATED","INTERVENTIONAL",[144],"PHASE4","The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.",[147],"Surgical Site Infection",[147,149],"SSI","2025-07-23",{"date":152,"type":153},"2025-07-28","ACTUAL",{"date":155,"type":153},"2023-01-17",{"date":157,"type":141},"2028-12",{"name":5,"class":6},4]